The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn More
Undergoing major gastrointestinal (GI) surgery can be challenging enough for a patient without the worry of a grave yet common aftereffect that requires urgent corrective surgery and a lengthy hospital stay – or worse. Israeli startup Exero Medical has come up with a way of keeping tabs on the surgical site after such a procedure, looking for a localized rupture that has hitherto been extremely difficult to detect. Every year, millions of people undergo surgery in the digestive tract – in most cases, for the removal of a part of the digestive system due to issues such as cancer or diverticulitis, Exero…
An Israeli professor is among 10 international recipients of an award for innovative neurobiological and behavioral research. Prof. Dorit Ben-Shachar from the Technion – Israel Institute of Technology is one of the 10 senior-level scientists to equally share the grant of $1 million from the Brain & Behavior Research Foundation (BBRF). Ben-Shachar aims to target mitochondria (the producers of energy within a cell) with a treatment that can help with biological and behavioral problems in schizophrenia. If successful, it can offer a better understanding of the role of mitochondria in schizophrenia, and potentially a new way of treating the condition.
The bacteria in the gut – known as the microbiome – have in recent years emerged as a focal point of scientific exploration, with their intricate roles in our metabolism, nutrition, and overall health coming into sharp focus. Researchers at the Technion-Israel Institute of Technology in Haifa have now made a discovery that could lead to a better understanding of and treatment for inflammatory bowel diseases (IBD) such as colitis and Crohn’s disease. Over millions of years of co-evolution with humans, gut bacteria have become indispensable for the proper functioning of our immune system. The gut is a constantly changing organ,…
An Israeli foodtech startup that makes milk and other dairy products from mushrooms has partnered with one of America’s biggest biotech companies, Ginkgo Bioworks, to scale-up and produce affordable animal-free non-whey dairy products. Haifa-based ImaginDairy has bioengineered milk protein to create a wide range of dairy products using mushrooms but no cows. Through a process called precision fermentation, ImaginDairy recreates these milk proteins in the lab and can use them to generate any kind of dairy product. The partnership aims to improve cost-effective production of non-whey dairy proteins. Ginkgo will utilize its AI capabilities to create biological systems that reduce the cost of production,…
Globally, there is a persistent shortage of viable organs for transplantation. This unmet need has spurred the development of “engineered organs” — cultivated tissue that mimics the structure and function of livers, hearts, lungs and other vital viscera. While these in-vitro inside parts can be used to fill the gap in organ supply, it’s really hard to supply blood throughout the newly transplanted tissue. To solve this problem, Bonus Biogroup, an Israeli biotechnology company specializing in next-generation tissue regeneration therapies, has developed a method of producing a sophisticated network of artificial blood vessels that will enable reliable blood flow to transplanted artificial organs, drastically…
This article is part of a special report on the total solar eclipse that will be visible from parts of the U.S., Mexico and Canada on April 8, 2024. CONCAN, Tex.—After months of waiting, planning and anticipating, the eclipse is nearly upon us. This rare heavenly alignment will be a marvel to look at for anyone lucky enough to have clear skies at the time. For a few minutes, the face of the moon will perfectly overlap that of the sun from our perspective on Earth, blocking out most of the light from our star and leaving only the wispy white glow…
No idea is too big in Start-Up Nation, and resilience and motivation are what make Israel’s bustling tech economy so successful. I recently had the pleasure of speaking with Omer Schneider, former CEO and co-founder of cybersecurity company CyberX, about his time at the Technion and how he took his big idea all the way to an acquisition deal with the largest tech company in the world. His dedication to his work in every stage of life gave him the confidence to believe in himself and make an impact on millions of people throughout his career. Omer’s story is also…
Programs, apps and websites are all built using code that tells a computer, phone or other device what to do and how to do it. Actually creating that code is a tricky and complicated process, where even the smallest error can cause entire platforms to fail. Finding a mistake in rows of letters and numbers can be even harder and is extremely time consuming. In fact, software developers can spend up to 50 percent of their working hours testing and debugging code, according to well-respected trade magazine ACM Queue. But now an Israeli company has developed an AI “team member”…
An Israeli medtech company whose novel therapy freezes and destroys malignant tumors has announced positive results in a trial of breast cancer patients. IceCure Medical’s ProSense system uses extremely cold liquid (cryoablation) to freeze and destroy abnormal tumors as an alternative to surgical removal. Its focus is currently on early-stage breast, lung, liver and kidney tumors. While cryoablation is not a new process, IceCure Medical’s system allows physicians to perform the procedure in their own offices, with no need for hospitalization. The company’s ICE3 study is the largest multicenter clinical trial performing cryoablation on low-risk and early-stage breast cancer tumors….
About 200 million people worldwide suffer from age-related macular degeneration (AMD), and that number is expected to increase to nearly 300 million by 2040. AMD is an eye disease that can blur central vision. It is the leading causes of blindness in Western countries, where people live long enough to experience such “first world” ocular issues. One in eight Westerners over the age of 60 can expect to develop AMD. Already in 2021, the market for AMD treatment was estimated at $7.4 billion. The United States made up 52% of that market, the European Union 41% and Japan just over…
An innovative, noninvasive Israeli medication administered through the nose hopes to be a life-changer for people suffering acute spinal cord injuries – even helping them to walk again. NurExone Biologic Inc. developed ExoPTEN, which treats damage to the nervous system, from a concept created by two members of its Scientific Advisory Board: Prof. Shulamit Levenberg of the Technion – Israel Institute of Technology and Prof. Daniel Offen from Tel Aviv University. (Another member of the board is Prof. Gabriel Zeilig, the head of the National Spinal Cord Injury Rehabilitation Unit at Sheba Medical Center, Israel’s largest and globally renowned hospital.)
The city that never sleeps is also, it seems, unable to take down scaffolding. New Yorkers have grown so sick of the ugly structures, and the accompanying ground-level cages in place to protect and divert pedestrians, that Eric Adams, the mayor, last year launched a campaign to clear them from the streets. Now computer scientists in the city have made a hit list of possible targets. Using ai to sift through thousands of hours of dashcam footage, the researchers identified some 5,000 scaffolding sites across all five boroughs, of which 500 were found to have no permit. “This city is the best…